Patents by Inventor Motomu Nakatake

Motomu Nakatake has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200289592
    Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a recombinant vaccinia virus lacking functions of VGF and O1L and having a gene encoding B5R in which an SCR domain has been deleted. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.
    Type: Application
    Filed: April 30, 2020
    Publication date: September 17, 2020
    Applicants: Astellas Pharma Inc., National University Corporation Tottori University
    Inventors: Takafumi Nakamura, Hajime KUROSAKI, Motomu NAKATAKE
  • Publication number: 20190367886
    Abstract: The present invention has an object to provide a vaccinia virus expressing a foreign gene and capable of killing cancer cells, and a cancer therapy drug comprising the vaccinia virus. The present invention relates to a vaccinia virus, wherein a suicide gene as a foreign gene selected from the group consisting of cytosine deaminase (CD) gene, uracil phosphoribosyltransferase (UPRT) gene, and herpes simplex virus thymidine kinase (HSV-tk) gene is introduced.
    Type: Application
    Filed: July 13, 2017
    Publication date: December 5, 2019
    Applicant: National University Corporation Tottori Tottori University
    Inventors: Takafumi Nakamura, Motomu Nakatake, Hajime Kurosaki, Kousuke Horita
  • Publication number: 20190336552
    Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a recombinant vaccinia virus lacking functions of VGF and O1L and having a gene encoding B5R in which an SCR domain has been deleted. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.
    Type: Application
    Filed: April 8, 2019
    Publication date: November 7, 2019
    Applicants: Astellas Pharma Inc., National University Corporation Tottori University
    Inventors: Takafumi Nakamura, Hajime KUROSAKI, Motomu NAKATAKE
  • Patent number: 10370647
    Abstract: It is an object of the present invention to provide utilization of a UCA1 gene that is a host regulatory factor that enhances replication and/or propagation of a vaccinia virus, in order to effectively carry out cancer virotherapy using the vaccinia virus. The present invention relates to: a method for predicting and evaluating the cancer therapeutic effects of a vaccinia virus, which comprises measuring the expression of a UCA1 gene in the cancer cells of a cancer patient, and then predicting that a vaccinia virus exhibits cancer therapeutic effects on the patient, when the UCA1 gene has been expressed therein; and a vaccinia virus into which a UCA1 gene has been expressibly introduced.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: August 6, 2019
    Assignee: National University Corporation Tottori University
    Inventors: Takafumi Nakamura, Kousuke Horita, Hajime Kurosaki, Motomu Nakatake
  • Publication number: 20180208904
    Abstract: It is an object of the present invention to provide utilization of a UCA1 gene that is a host regulatory factor that enhances replication and/or propagation of a vaccinia virus, in order to effectively carry out cancer virotherapy using the vaccinia virus. The present invention relates to: a method for predicting and evaluating the cancer therapeutic effects of a vaccinia virus, which comprises measuring the expression of a UCA1 gene in the cancer cells of a cancer patient, and then predicting that a vaccinia virus exhibits cancer therapeutic effects on the patient, when the UCA1 gene has been expressed therein; and a vaccinia virus into which a UCA1 gene has been expressibly introduced.
    Type: Application
    Filed: July 22, 2016
    Publication date: July 26, 2018
    Inventors: Takafumi Nakamura, Kousuke Horita, Hajime Kurosaki, Motomu Nakatake